Cargando…
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cells will likely continue to expand with the develop...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327099/ https://www.ncbi.nlm.nih.gov/pubmed/32670871 http://dx.doi.org/10.3389/fonc.2020.00885 |